Angela Mastronuzzi: GD2-Targeting therapy for GD2+ Medulloblastoma
Angela Mastronuzzi shared a post on LinkedIn:
”GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma.
Authors: Roselia Ciccone, Concetta Quintarelli, Antonio Camera, Michele Pezzella, Simona Caruso, Simona Manni, Alessio Ottaviani, Marika Guercio, Francesca Del Bufalo, Maria Cecilia Quadraccia, Domenico Orlando, Stefano Di Cecca, Matilde Sinibaldi, Mariasole Aurigemma, Laura Iaffaldano, Andrea Sarcinelli, Maria Luisa D’Amore, Manuela Ceccarelli, Francesca Nazio, Veronica Marabitti, Ezio Giorda, Marco Pezzullo, Cristiano De Stefanis, Andrea Carai, Sabrina Rossi, Rita Alaggio, Giada Del Baldo, Marco Becilli, Angela Mastronuzzi, Biagio De Angelis, Franco Locatelli.
The article has just been published with Clinical Cancer Research from the American Association for Cancer Research.
Our experimental data indicate the potential efficacy of CAR.GD2 T-cell therapy. A phase I/II clinical trial is ongoing in our center (NCT05298995) to evaluate the safety and therapeutic efficacy of CAR.GD2 therapy in high-risk medulloblastoma patients.”
Source: Angela Mastronuzzi/LinkedIn
Angela Mastronuzzi is pediatric hematologist-oncologist and the Head of Neuro-Oncology Unit at Bambino Gesù Children’s Hospital (Italy). She is also a professor at the UniCamillus International Medical University, and a Board Member of AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica). Her main fields of interest are CNS tumors and innovative therapies.